RHÖN-KLINIKUM AG Reports Solid 2025 Results with Focus on Technological Investments Amid Industry Challenges

RHÖN-KLINIKUM AG concluded the 2025 financial year with solid performance, meeting its financial targets despite challenging health policy and economic conditions. The group reported a 6.8% increase in consolidated revenues to €1,704.7 million, with patient numbers rising by 2.5% to 938,650 across its clinics and medical care centers. Earnings before interest, tax, depreciation, and amortization (EBITDA) reached €105.9 million, while consolidated profit decreased to €36.3 million due to higher depreciation and impairment of fixed assets along with declining interest rates.

Dr. Stefan Stranz, a member of the Board of Management, emphasized the group's positive economic development within Germany's tense hospital industry environment. He highlighted the importance of cooperation within the corporate group with ASKLEPIOS as a key success factor. The company launched further clinic development measures throughout 2025, adding new care offerings at all locations to expand outpatient and inpatient treatment options. A significant development was the establishment of a joint breast center at the university locations in Gießen and Marburg, setting new standards in oncological care for the Hesse region.

Dr. Gunther K. WeiB, another Board of Management member, noted that the group's financial stability enables targeted investments in medical high-tech equipment. In 2025, these investments included a new laboratory line in Giessen, advanced cardiac catheter technologies and a new 3 Tesla magnetic resonance tomograph in Marburg, and a radiotherapy system for cancer treatment in Bad Berka. The company also implemented photon counting computer tomography technology, becoming the only hospital group with three of these latest-generation systems in operation, with further investments planned. The complete financial details are available in the Annual Report 2025 published online.

For the 2026 financial year, RHÖN-KLINIKUM AG forecasts revenues of approximately €1.7 billion within a range of plus or minus 5%, with EBITDA expected between €110 million and €125 million. The group also anticipates moderate increases in non-financial performance indicators including case numbers and cost weights. This outlook accounts for heightened regulatory interference by German legislators and the implementation of hospital reform measures. The company notes considerable uncertainties related to global crises affecting prices and supply chains, along with potential regulatory changes impacting medical service remuneration structures in 2026.